US regulatory advisors are backing the claim that Novo Nordisks’ Victoza reduces cardiovascular risk in patients with diabetes. http://www.pharmatimes.com/news/novo_gets_us_backing_for_victoza_cardiovascular_data_1196325
Novo Nordisk has filed its once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide with regulators on both sides of the Atlantic, seeking permission to market the drug for the treatment of adults with type II diabetes. http://www.pharmatimes.com/news/novo_files_once-weekly_glp-1_analogue_semaglutide_1180190
The U.S. Food and Drug Administration approved Adlyxin (lixisenatide), a once-daily injection to improve glycemic control (blood sugar levels), along with diet and exercise, in adults with type 2 diabetes. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm513602.htm
(Reuters) – Novo Nordisk’s top-selling diabetes drug Victoza cut the risk of heart attack, stroke and cardiovascular death by 13 percent in a closely watched study that may help boost sales of the injectable medicine. http://www.reuters.com/article/us-health-diabetes-novo-nordisk-idUSKCN0YZ2F7
For the second time in just over a month, Novo Nordisk releases positive data for a GLP-1 agonist for type 2 diabetes; this time it’s for the once-weekly injection semaglutide, which is not yet approved. Medscape Medical News http://www.medscape.com/viewarticle/862644
COPENHAGEN (Reuters) – Novo Nordisk said on Friday the results from a trial showed that its Victoza diabetes drug significantly reduced the risks of major adverse cardiovascular events.
The weekly diabetes candidate semaglutide successfully completed four prior phase 3 trials, which compared Novo’s next-gen hopeful to existing treatments. http://www.biopharmadive.com/news/novo-nordisk-notches-another-phase-3-success-for-glp-1-drug/414525/